|A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome.
|Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome.
|Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance.
|Point mutations detected in the androgen receptor gene of three men with partial androgen insensitivity syndrome.
|A unique point mutation in the androgen receptor gene in a family with complete androgen insensitivity syndrome.
|Mutations in the ligand-binding domain of the androgen receptor gene cluster in two regions of the gene.
|Androgen resistance due to mutation of the androgen receptor.
|Immunoreactive androgen receptor expression in subjects with androgen resistance.
|Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique.
|Point mutation in the steroid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome (CAIS).
|Trinucleotide repeat polymorphism in the androgen receptor gene (AR).
|The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
|A single amino acid substitution (Met-786-->Val) in the steroid-binding domain of human androgen receptor leads to complete androgen insensitivity syndrome.
|Replacement of arginine 773 by cysteine or histidine in the human androgen receptor causes complete androgen insensitivity with different receptor phenotypes.
|Androgen receptor gene mutations in human prostate cancer.
|Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics.
|Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg-->Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function.
|A mutation in the DNA-binding domain of the androgen receptor gene causes complete testicular feminization in a patient with receptor-positive androgen resistance.
|Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy.
|Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.
|Functional characterization of naturally occurring mutant androgen receptors from subjects with complete androgen insensitivity.
|A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.
|Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance.
|Specific region in hormone binding domain is essential for hormone binding and trans-activation by human androgen receptor.
|Structural organization of the human androgen receptor gene.
|Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity.
|Characterization and expression of a cDNA encoding the human androgen receptor.
|The N-terminal domain of the human androgen receptor is encoded by one, large exon.
|Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors.
|The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate.
|Molecular cloning of human and rat complementary DNA encoding androgen receptors.
|Cloning of human androgen receptor complementary DNA and localization to the X chromosome.
|Cloning, structure and expression of a cDNA encoding the human androgen receptor.
|Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer.
|Leu-676-Pro mutation of the androgen receptor causes complete androgen insensitivity syndrome in a large Hutterite kindred.
|Human androgen insensitivity due to point mutations encoding amino acid substitutions in the androgen receptor steroid-binding domain.
|Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding.
|Androgen receptor mutations.
|Characterization of alternative amino acid substitutions at arginine 830 of the androgen receptor that cause complete androgen insensitivity in three families.
|Genetic counselling in complete androgen insensitivity syndrome: trinucleotide repeat polymorphisms, single-strand conformation polymorphism and direct detection of two novel mutations in the androgen receptor gene.
|A single amino acid exchange abolishes dimerization of the androgen receptor and causes Reifenstein syndrome.
|Androgen receptor defects: historical, clinical, and molecular perspectives.
|Mutations of the androgen receptor coding sequence are infrequent in patients with isolated hypospadias.
|Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men.
|Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
|Molecular prenatal exclusion of familial partial androgen insensitivity (Reifenstein syndrome).
|Molecular prenatal diagnosis of partial androgen insensitivity syndrome based on the Hind III polymorphism of the androgen receptor gene.
|Amino acid substitutions in the hormone-binding domain of the human androgen receptor alter the stability of the hormone receptor complex.
|The androgen receptor gene mutations database.
|An androgen receptor mutation causing androgen resistance in undervirilized male syndrome.
|A practical approach to the detection of androgen receptor gene mutations and pedigree analysis in families with X-linked androgen insensitivity.
|Detection of point mutations in the androgen receptor gene using non-isotopic single strand conformation polymorphism analysis.
|Two mutations causing complete androgen insensitivity: a frame-shift in the steroid binding domain and a Cys-->Phe substitution in the second zinc finger of the androgen receptor.
|Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene.
|Molecular characterization of the androgen receptor gene in boys with hypospadias.
|Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance.
|Complete androgen insensitivity syndrome associated with a de novo mutation of the androgen receptor gene detected by single strand conformation polymorphism.
|Mutations of the androgen receptor gene identified in perineal hypospadias.
|An exonic point mutation creates a MaeIII site in the androgen receptor gene of a family with complete androgen insensitivity syndrome.
|Characterization of mutant androgen receptors causing partial androgen insensitivity syndrome.
|Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
|Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptor.
|Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.
|Single amino acid substitution (840Arg-->His) in the hormone-binding domain of the androgen receptor leads to incomplete androgen insensitivity syndrome associated with a thermolabile androgen receptor.
|Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation.
|A new mutation within the deoxyribonucleic acid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome.
|Mutations of androgen receptor gene in androgen insensitivity syndromes.
|Androgen receptor gene mutations in human prostate cancer.
|Androgen receptor gene mutation in male breast cancer.
|A single-base substitution in exon 6 of the androgen receptor gene causing complete androgen insensitivity: the mutated receptor fails to transactivate but binds to DNA in vitro.
|Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer.
|A single amino acid substitution (Gly743 --> Val) in the steroid-binding domain of the human androgen receptor leads to Reifenstein syndrome.
|Single strand conformation polymorphism analysis of androgen receptor gene mutations in patients with androgen insensitivity syndromes: application for diagnosis, genetic counseling, and therapy.
|Molecular genetics of human androgen insensitivity.
|A point mutation in the second zinc finger of the DNA-binding domain of the androgen receptor gene causes complete androgen insensitivity in two siblings with receptor-positive androgen resistance.
|Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotypes.
|Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol.
|Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-->Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels.
|A novel substitution (Leu707Arg) in exon 4 of the androgen receptor gene causes complete androgen resistance.
|Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis.
|Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations.
|Androgen receptor gene mutations are rarely associated with isolated penile hypospadias.
|The clinical and molecular spectrum of androgen insensitivity syndromes.
|Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene.
|Androgen insensitivity syndrome due to new mutations in the DNA-binding domain of the androgen receptor.
|A novel missense mutation in the amino-terminal domain of the human androgen receptor gene in a family with partial androgen insensitivity syndrome causes reduced efficiency of protein translation.
|Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndrome.
|Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.
|A frame-shift mutation of the androgen receptor gene in a patient with receptor-negative complete testicular feminization: comparison with a single base substitution in a receptor-reduced incomplete form.
|Molecular basis of androgen insensitivity.
|Mutations of the androgen receptor gene in patients with complete androgen insensitivity.
|Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
|Rapid detection of a mutation hot-spot in the human androgen receptor.
|Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene.
|The androgen receptor gene mutations database.
|Clinical and biochemical investigations and molecular analysis of subjects with mutations in the androgen receptor gene.
|The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.
|Germ-line and somatic mosaicism in the androgen insensitivity syndrome: implications for genetic counseling.
|Molecular analysis of androgen resistance syndromes in Egyptian patients.
|Androgen receptor gene mutations in prostate cancer.
|Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome.
|Complete androgen insensitivity syndrome. Molecular characterization in two Chinese women.
|DNA analysis of the androgen receptor gene in two cases with complete androgen insensitivity syndrome.
|Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome.
|Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome.
|Etiologic classification of severe hypospadias: implications for prognosis and management.
|Genetic alterations of androgen receptor gene in Japanese human prostate cancer.
|Response to androgen treatment in a patient with partial androgen insensitivity and a mutation in the deoxyribonucleic acid-binding domain of the androgen receptor.
|Molecular analysis of the androgen receptor gene in 4 patients with complete androgen insensitivity.
|A new missense substitution at a mutational hot spot of the androgen receptor in siblings with complete androgen insensitivity syndrome.
|An androgen receptor gene mutation (A645D) in a boy with a normal phenotype.
|Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
|One additional mutation at exon A amplifies thermolability of androgen receptor in a case with complete androgen insensitivity syndrome.
|Inherited and de novo androgen receptor gene mutations: investigation of single-case families.
|Mutations of androgen receptor gene in Brazilian patients with male pseudohermaphroditism.
|Trafficking of androgen receptor mutants fused to green fluorescent protein: a new investigation of partial androgen insensitivity syndrome.
|Analysis of the transactivation domain of the androgen receptor in patients with male infertility.
|Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
|Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation.
|Functional characterisation of mutations in the ligand-binding domain of the androgen receptor gene in patients with androgen insensitivity syndrome.
|Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.
|Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.
|Screening for mutations in candidate genes for hypospadias.
|Androgen receptor gene mutations in 46,XY females with germ cell tumours.
|An androgen receptor mutation in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core is associated with complete androgen insensitivity.
|PQBP-1, a novel polyglutamine tract binding protein, inhibits transcription activation by Brn-2 and affects cell survival.
|Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
|Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription.
|The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator.
|A case of complete testicular feminization: laparoscopic orchiectomy and analysis of androgen receptor gene mutation.
|Point mutations in the steroid-binding domain of the androgen receptor gene of five Japanese patients with androgen insensitivity syndrome.
|A new point mutation of the androgen receptor gene in a patient with partial androgen resistance and severe oligozoospermia.
|A novel point mutation (R840S) in the androgen receptor in a Brazilian family with partial androgen insensitivity syndrome.
|Directed pharmacological therapy of ambiguous genitalia due to an androgen receptor gene mutation.
|Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
|Analysis of exon 1 mutations in the androgen receptor gene.
|Clinical and molecular spectrum of somatic mosaicism in androgen insensitivity syndrome.
|A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1.
|PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression.
|Androgen receptor gene mutations in hormone-refractory prostate cancer.
|Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome.
|Androgen receptor mutations in prostate cancer.
|Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.
|Androgen receptor interacts with a novel MYST protein, HBO1.
|Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).
|Polymorphism of the androgen receptor gene is associated with male pattern baldness.
|Eight novel mutations of the androgen receptor gene in patients with androgen insensitivity syndrome.
|Characterization of a novel receptor mutation A->T at exon 4 in complete androgen insensitivity syndrome and a carrier sibling via bidirectional polymorphism sequence analysis.
|Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.
|Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment. Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor.
|RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor.
|Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.
|DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex.
|The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway.
|Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling.
|hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci.
|The retinoblastoma protein-associated transcription repressor RBaK interacts with the androgen receptor and enhances its transcriptional activity.
|Concordance of phenotypic expression and gender identity in a large kindred with a mutation in the androgen receptor.
|The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
|Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.
|The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.
|Androgen receptor function is modulated by the tissue-specific AR45 variant.
|The DNA sequence of the human X chromosome.
|A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy.
|Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.
|Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors.
|hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes.
|Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.
|Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.
|Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.
|Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells.
|Regulation of androgen receptor activity by tyrosine phosphorylation.
|Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
|Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
|The zinc finger protein Ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer.
|PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.
|Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
|Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12.
|A surface on the androgen receptor that allosterically regulates coactivator binding.
|Interaction between the androgen receptor and a segment of its corepressor SHP.
|ZIP kinase plays a crucial role in androgen receptor-mediated transcription.
|RanBP10 acts as a novel coactivator for the androgen receptor.
|Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.
|TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.
|A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
|Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.
|TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells.
|The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling.
|Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
|CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.
|System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
|MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.
|DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors.
|Cryptochromes mediate rhythmic repression of the glucocorticoid receptor.
|The androgen receptor gene mutations database: 2012 update.
|CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2.
|An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
|Analysis of protein-coding genetic variation in 60,706 humans.